Literature DB >> 1991513

Non-viral cellular substrates for human immunodeficiency virus type 1 protease.

R L Shoeman1, C Kesselmier, E Mothes, B Höner, P Traub.   

Abstract

A computer search revealed 10 proteins with homology to the sequence we originally identified in vimentin as the site of cleavage by human immunodeficiency virus type 1 (HIV-1) protease. Of these 10 proteins (actin, alpha-actinin, spectrin, tropomyosins, vinculin, dystrophin, MAP-2, villin, TRK-1 and Ig mu-chain), we show that 4 of the first 5 were cleaved in vitro by this protease, as are MAP-1 and -2 [(1990) J. Gen. Virol. 71, 1985-1991]. In these proteins, cleavage is not restricted to a single motif, but occurs at many sites. However, cleavage is not random, since 9 other proteins including the cytoskeletal proteins filamin and band 4.1 are not cleaved in the in vitro assay. Thus, the ability of HIV-1 protease to cleave specific components of the cytoskeleton may be an important, although as yet unevaluated aspect of the life cycle of this retrovirus and/or may directly contribute to the pathogenesis observed during infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1991513     DOI: 10.1016/0014-5793(91)80116-k

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  Reversible oxidative modification as a mechanism for regulating retroviral protease dimerization and activation.

Authors:  David A Davis; Cara A Brown; Fonda M Newcomb; Emily S Boja; Henry M Fales; Joshua Kaufman; Stephen J Stahl; Paul Wingfield; Robert Yarchoan
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation.

Authors:  H G Kräusslich
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

3.  Actin associates with the nucleocapsid domain of the human immunodeficiency virus Gag polyprotein.

Authors:  T Wilk; B Gowen; S D Fuller
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

4.  Amino-terminal polypeptides of vimentin are responsible for the changes in nuclear architecture associated with human immunodeficiency virus type 1 protease activity in tissue culture cells.

Authors:  R L Shoeman; C Hüttermann; R Hartig; P Traub
Journal:  Mol Biol Cell       Date:  2001-01       Impact factor: 4.138

5.  Cleavage of human and mouse cytoskeletal and sarcomeric proteins by human immunodeficiency virus type 1 protease. Actin, desmin, myosin, and tropomyosin.

Authors:  R L Shoeman; C Sachse; B Höner; E Mothes; M Kaufmann; P Traub
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

6.  Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease.

Authors:  Dirk Jochmans; Maria Anders; Inge Keuleers; Liesbeth Smeulders; Hans-Georg Kräusslich; Günter Kraus; Barbara Müller
Journal:  Retrovirology       Date:  2010-10-15       Impact factor: 4.602

7.  Cholesterol depletion of human immunodeficiency virus type 1 and simian immunodeficiency virus with beta-cyclodextrin inactivates and permeabilizes the virions: evidence for virion-associated lipid rafts.

Authors:  David R M Graham; Elena Chertova; Joanne M Hilburn; Larry O Arthur; James E K Hildreth
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Interaction between the cytoplasmic domain of ICAM-1 and Pr55Gag leads to acquisition of host ICAM-1 by human immunodeficiency virus type 1.

Authors:  Yannick Beauséjour; Michel J Tremblay
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

Review 9.  How HIV takes advantage of the cytoskeleton in entry and replication.

Authors:  Bettina Stolp; Oliver T Fackler
Journal:  Viruses       Date:  2011-03-28       Impact factor: 5.048

10.  Altered gene expression in asymptomatic SHIV-infected rhesus macaques (Macacca mulatta).

Authors:  Erica E Carroll; Rasha Hammamieh; Nabarun Chakraborty; Aaron T Phillips; Stacy-Ann M Miller; Marti Jett
Journal:  Virol J       Date:  2006-09-06       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.